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The enzyme lysostaphin possesses potent anti-
staphylococcal activity and represents a promising
antibacterial drug candidate; however, its immuno-
genicity poses a barrier to clinical translation.
Here, structure-based biomolecular design enabled
widespread depletion of lysostaphin DRB1*0401
restricted T cell epitopes, and resulting deimmunized
variants exhibited striking reductions in anti-drug
antibody responses upon administration to human-
ized HLA-transgenic mice. This reduced immunoge-
nicity translated into improved efficacy in the form of
protection against repeated challenges with methi-
cillin-resistant Staphylococcus aureus (MRSA). In
contrast, while wild-type lysostaphin was efficacious
against the initial MRSA infection, it failed to clear
subsequent bacterial challenges that were coinci-
dent with escalating anti-drug antibody titers. These
results extend the existing deimmunization literature,
in which reduced immunogenicity and retained effi-
cacy are assessed independently of each other. By
correlating in vivo efficacy with longitudinal mea-
sures of anti-drug antibody development, we provide
the first direct evidence that T cell epitope depletion
manifests enhanced biotherapeutic efficacy.
INTRODUCTION
Biotherapeutics represent a growing share of the pharmaceuti-
cals market (Aggarwal, 2014), and are expected to become
increasingly important as new molecules are brought forward
to address an ever wider array of indications. While these biolog-
ical agents generally benefit from exceptional specificity and po-
tency, they are also subject to unique risk factors that distinguish
them from conventional small-molecule drugs. In particular, pro-
teins are susceptible to human immune surveillance and have aChemistry & Biology 22,propensity to elicit anti-drug antibodies, which can compromise
efficacy and even threaten patient safety. Protein immunoge-
nicity can be caused by a wide variety of factors (Schellekens,
2002; Jawa et al., 2013), with one important driver being the
origin of a protein: non-human proteins are predisposed toward
immune recognition as foreign agents. Due in part to concerns
over immunogenicity, a promising reservoir of drug candidates
from the broader biosphere has been left largely untapped,
and fully exploiting themedicinal potential of exogenous proteins
will require effective strategies by which to mitigate immunoge-
nicity risks.
The antibacterial enzyme lysostaphin (LST) is one bio-
therapeutic candidate whose clinical development has been
stymied in part by immunogenicity concerns. LST is a peptido-
glycan-degrading biocatalyst with potent and selective bacteri-
cidal activity toward the dangerous human pathogen Staphylo-
coccus aureus (Szweda et al., 2012). It has been shown to be
efficacious in a wide variety of preclinical animal models, and
has been proved capable of clearing human nasal carriage of
S. aureus and even clearing a drug-resistant systemic infection
in one patient (Stark et al., 1974). Unfortunately the bacterial
origin of LST, which is derived from the S. aureus environmental
competitor Staphylococcus simulans, contribute to a variety
of immunogenicity-related issues in mice, rats, rabbits, dogs,
non-human primates, and even human subjects (Kokai-Kun,
2012).
As with many biotherapeutics, T cell epitopes are one likely
driver of the immunogenicity of lysostaphin. Upon administration
of LST or any foreign protein to a human subject, antigen-
presenting cells sample the agent from the extracellular environ-
ment and proteolytically degrade it within lysosomal compart-
ments. A subset of peptide fragments, known as T cell epitopes,
are loaded into the groove of class II major histocompatibility
complex proteins (MHC II, also called HLA in humans). The
MHC-bound peptides are then presented on the cell surface,
where they have the opportunity to form ternary complexes
with cognate receptors on the surface of CD4+ helper T cells
(Trombetta and Mellman, 2005). Simultaneous engagement of
co-receptors generates an immune synapse, which initiates a
signaling cascade that ultimately drives T cell activation, B cell629–639, May 21, 2015 ª2015 Elsevier Ltd All rights reserved 629
Figure 1. Schematic Overview of Molecular
Engineering Process and In Vivo Outcomes
(Top) A plot of molecular fitness versus immuno-
genicity is shown for individually optimized variants
and selected library members. The y axis reflects
trends in experimental performance measure-
ments and the x axis reflects trends in computa-
tional predictions of T cell epitope content. LSTWT
has both high fitness and high immunogenicity,
where the latter is shown as a structural epitope
map (gray) (thick red indicates dense epitope
content and thin gray indicates no epitope con-
tent). Deimmunization by design of individual
optimal variants is shown in blue, where the initial
design was fully depleted of DR4 epitopes, but
failed to express. Subsequent designs reverted
problematic mutations in a reverse engineering
process, ultimately yielding the expressible,
aglycosylated, but inactive variant Opt4, whose
structural epitope map is shown (blue). Deimmu-
nization by library design and screening is shown
in green. Deimmunizing mutations were accumu-
lated in an iterative process, ultimately yielding the
active and deimmunized Lib5 variant, whose
structural epitope map is shown (green).
(Bottom) The in vivo immunogenicities of LSTWT,
Opt4, and Lib5 were evaluated in transgenic DR4
mice, and trends in observed antibody titers are
indicated as Y-shaped IgG cartoons in the mice.
Subsequently, the efficacy of LSTWT and Lib5 were
evaluated in a recurrent bacteremia model that
required repeated dosing of the antibacterial
enzyme. Variant Lib5 enabled repeated rescue of
DR4mice, whereas LSTWT lost efficacy due to high
antibody titers. See also Table S1.maturation, and production of circulating immunoglobulin G
(IgG) antibodies that bind to the offending therapeutic protein
(Jawa et al., 2013). Thus, a T cell-mediated anti-drug antibody
response is fundamentally driven by molecular recognition of
peptide fragments derived from the therapeutic agent.
It has been well established that mutagenic deletion of a pro-
tein’s constituent epitopes can reduce immunogenic potential.
In some instances, a foreign protein may contain only one or
two immunodominant regions that are readily deleted with a
small number of mutations (Cizeau et al., 2009; Harding et al.,
2005). In other cases, proteins may contain a larger number of
distributed epitopes. In such a scenario, redesigning one region
might remain relatively straightforward (Warmerdam et al., 2002;
Mazor et al., 2012), but aggressive deimmunization targeting
multiple dispersed epitopes represents amore serious challenge
requiring extensive experimental effort (Mazor et al., 2014). As a
complement to experimentally driven methods, computational
epitope predictors and computational modeling of the structural
and functional consequences of epitope-deleting mutations can
accelerate the deimmunization process. In particular, fully inte-
grated protein design and deimmunization tools have the capac-
ity to rapidly identify candidate epitopes and quickly select the
most promising deimmunizing mutations (Parker et al., 2010,
2011, 2013; He et al., 2012; Choi et al., 2013; King et al., 2014).
Several experimental studies of designs produced by various
algorithms have yielded promising results based on surrogate
measures of immunogenicity (i.e., peptide-MHC II binding as-630 Chemistry & Biology 22, 629–639, May 21, 2015 ª2015 Elseviersays and/or ex vivo cellular immunoassays) (King et al., 2014;
Osipovitch et al., 2012; Salvat et al., 2014, 2015). However, the
ultimate goal of protein deimmunization is the mitigation of
anti-drug antibody responses so as to enhance efficacy, and
assessing such an outcome is currently only possible in vivo.
Here, we sought to assess the effects of LST epitope depletion
using clinically relevant metrics. Structure-based design of indi-
vidual variants and structure-based library design accelerated
the deimmunization process, and the performance of engi-
neered variants was compared with the parental wild-type
enzyme in HLA-transgenic mice. Longitudinal measures of
anti-drug antibody development correlated with in vivo anti-
bacterial activity, thereby providing the first direct evidence
that protein deimmunization manifests enhanced biotherapeutic
efficacy.
RESULTS
Overview
In this study, we sought to test the hypothesis that depletion of
putative T cell epitopes in LST would mitigate the anti-drug anti-
body response and consequently enhance therapeutic efficacy.
Epitope-depleted variants were developed using two distinct
computationally guided strategies: structure-based design of
individual deimmunized variants followed by empirical improve-
ment (Figure 1, blue path) and structure-based design and
screening of combinatorial libraries enriched in functionallyLtd All rights reserved
Figure 2. Epitope Maps of LST Enzymes
(A) Predicted DR4 T cell epitopes are shown for
variants Lib5 (top), Opt4 (middle), and LSTWT
(bottom). Nonamer epitopes are shown as black
horizontal lines at the corresponding position in the
LST amino acid sequence (x axis). LSTWT contains
16 putative epitopes, Opt4 contains 5, and Lib5
contains only 3. Regions of overlapping epitope
density in LSTWT are highlighted with colored
blocks (x axis). Positions of deimmunizing muta-
tions in Lib5 are shown as vertical green bars (top),
and those in Opt4 as vertical blue bars (middle).
The mutation and epitope counts for each design
are indicated on the right.
(B) Predicted epitopes in LSTWT aremapped onto a
structural model. Thick red tubes indicate dense
overlapping epitopes, and thin white tubes indicate
absence of epitopes. High-density regions from
the sequence map are highlighted in the structural
model with corresponding background coloring.
The P1 anchor residue of the first epitope in each
cluster is annotated.
(C) Predicted epitopes remaining in Opt4 are
mapped onto a structural model.
(D) Predicted epitopes remaining in Lib5 are map-
ped onto a structural model. See also Figure S1.deimmunized members (Figure 1, green path). Humanized HLA-
transgenic mice were used to assess the efficiency with which
each method deleted putative immunogenic epitopes and
thereby prevented formation of anti-LST antibodies in vivo (Fig-
ure 1, bottom). Subsequently, a recurrent bacteremia model was
used to gauge the extent to which LST deimmunization enabled
clearance of systemicS. aureus infections. This systematic com-
parison between deimmunized variants and their wild-type
counterpart provides direct experimental evidence of the clini-
cally relevant connections between putative T cell epitopes,
in vivo immunogenicity, and therapeutic efficacy.
As a proof of concept, we focused on allele DRB1*0401
(hereafter referred to as DR4), which is highly prevalent in North
American and European populations. At a 5% threshold (i.e.,
peptides among the top 5% of predicted binders), the ProPred
analysis tool (Singh and Raghava, 2001) predicted 16 DR4
restricted T cell epitopes within wild-type LST (LSTWT epitope
score = 16). The peptide epitopes were arrayed as both overlap-
ping clusters and isolated nonamers distributed throughout the
sequence and structure of the protein (Figures 2A and 2B). Inter-
estingly, ProPred predicted more epitopes for DR4 than for any
of the seven other representative DRB1 alleles 0101, 0301,
0701, 0801, 1101, 1301, and 1501 (Figure S1). Considering any
single allele, therefore, our chosen DR4 model represented a
‘‘high bar’’ for global protein redesign.
To select combinations of mutations likely to preserve struc-
tural integrity while deleting predicted epitopes, it was necessary
to develop a homology model of LST, as no crystal structure was
available at the initiation of our studies. LST is a two-domain
protein with a cell wall binding domain that targets S. aureusChemistry & Biology 22, 629–639, May 21, 2015peptidoglycan and a catalytic domain
that specifically cleaves the pentaglycine
crosslinks in the cell wall, causing rapidbacterial lysis and death. We separately modeled and rede-
signed the catalytic domain and the cell wall binding domain.
Recently a crystal structure was obtained of both domains
together (Sabala et al., 2014), and our models displayed tem-
plate modelling score (TM-score) (Zhang and Skolnick, 2004)
of 0.88 for the catalytic domain and 0.95 for the cell wall binding
domain, indicating a high level of agreement. The primary differ-
ences between the homology model and LST crystal structure
were associated with loops surrounding active sites. Consistent
with observations on a homologous protein (Firczuk et al., 2005),
the corresponding loop structures are highly variable (Figure S2).
Thus, the model deviations were relatively minor, and indeed the
model ultimately proved useful in guiding LST redesign.
Structure-Based Design of Individual Variants
The EpiSweep algorithm (Parker et al., 2013) was used to opti-
mize deimmunized variants, making the best trade-offs between
predicted reduction in epitope content, as evaluated by ProPred,
and predicted maintenance of protein stability, as evaluated
by structure-based rotamer energy. Panels of 20 fully depleted
designs (i.e., DR4 epitope scores = 0) were generated separately
for both the catalytic and cell wall binding domains. A variant
combining low-energy designs from each domain, Opt1
(Table 1), was selected for experimental analysis and cloned
into an optimized Pichia pastoris expression system (Zhao
et al., 2014). Unfortunately, this 14-mutation design failed to yield
functional protein (Figure 1). Other LST redesignwork had shown
that single mutations could undermine otherwise stable and
active deimmunized variants (Blazanovic et al., 2015), and we
therefore identified detrimental mutations in the Opt1 designª2015 Elsevier Ltd All rights reserved 631
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632 Chemistry & Biology 22, 629–639, May 21, 2015 ª2015 Elsevierby systematically reverting mutations and mutation combina-
tions. Analysis of isolated Opt1 mutations revealed that M119R
singlehandedly abolished protein secretion, but reversion of
this single mutation in design Opt2 (Table 1) failed to restore
expression (Figure 1). Ultimately, it was found that the three-mu-
tation combination S166E, S168K, and V193W also undermined
expression, and reversion to wild-type at these three sites in
addition to M119 generated an expressible ten-mutation variant,
Opt3 (Figure 1).
Although Opt3 achieved reasonable expression levels
(Table 1), purity analysis by SDS-PAGE revealed two bands:
one at the expected 25 kDamass and a second at approximately
30 kDa. Based on prior experience with LST glycosylation in
P. pastoris (Zhao et al., 2014), we suspected that a latent
N-linked glycosylation sequon in the C-terminal cell wall binding
domain (232-NKS-234) had been activated. We therefore
exchanged the deimmunizing N236D mutation with the S234K
mutation, which deleted both the C-terminal epitope and the
N-linked glycosylation sequon. The resulting ten-mutation
variant, Opt4, bore only five predicted DR4 epitopes and ex-
pressed as a single 25 kDa band, albeit with lower yields than
Opt3 (Figure 1). Although the highly engineered Opt4 variant
was produced in a folded and secretion-competent state, it
was subsequently found to possess only a small fraction of the
antibacterial activity of the wild-type enzyme (Table 1).
Structure-Based Deimmunization via Computational
Library Design
In parallel with design of individual variants, we also pursued an
alternative combinatorial approach in which computational
design was used to generate LST libraries predicted to be en-
riched in functional, deimmunized variants. The structure-based
library design method SOCoM (Verma et al., 2015) was
augmented with epitope analysis to identify residue positions
and mutations whose combinations yielded variants with low
epitope scores, as evaluated by ProPred, along with good en-
ergies, as evaluated by a Cluster Expansion (Grigoryan et al.,
2009, 2006) potential trained on Rosetta (Rohl et al., 2004)
models. In the initial round, the designs were based on the
wild-type reference, while in succeeding rounds the reference
was shifted to the lead clone selected from the previous library
screen.
Library A targeted nine sites in the catalytic domain, and the
complementary library B population targeted eight sites in the
cell wall binding domain (Table S1). Although the deimmunized
LST design space was massive, we constrained our initial li-
braries to fewer than 40,000 members so as to maintain some
parity between library size and the screening capacity of agar
plate halo formation assays. Approximately 10,000 clones
were screened from both libraries A and B, and ten large-halo-
forming colonies from each were sequenced and functionally
validated. The most promising variant from library A (clone
Lib1, Figure 1) contained four mutations in the catalytic domain
and exerted antibacterial activity equivalent to LSTWT (Table 1).
Likewise, the most promising variant from library B (clone Lib2,
Figure 1) possessed four mutations in the cell wall binding
domain and also had wild-type antibacterial activity (Table 1).
The respective deimmunized domains of variants Lib1 and
Lib2 were combined to produce variant Lib3 (Figure 1),Ltd All rights reserved
Figure 3. In Vivo Immunogenicity of LST and Deimmunized Candidates, as Measured by Anti-LST IgG Antibody ELISA Following Immuniza-
tion in Complete Freund’s Adjuvant
(A) Immunogenicity of LSTWT and Opt4 in humanized DR4 mice. LSTWT immunized mice exhibit high antibody titers (gray), whereas Opt4 immunized mice (blue)
have titers at or near background levels seen with a PBS sham immunization (magenta).
(B) Immunogenicity of LSTWT and Lib5 in humanized DR4mice. One Lib5 immunizedmouse (green) exhibited antibody titers equivalent to those elicited by LSTWT
(gray), with three mice having one to two orders of magnitude lower titers and a fifth mouse near PBS background levels (magenta).
(C) Immunogenicity of LSTWT (gray) and Opt4 (blue) in the C57Bl/6 stock mouse strain. Both enzymes are equally immunogenic.
(D) Immunogenicity of LSTWT (gray) and Lib5 (green) in stock C57BL/6 mice. Both LSTWT and Lib5 were highly immunogenic, with Lib5 representing the stronger
antigen.
Together, these results demonstrate that the striking reduction in Opt4 and Lib5 immunogenicity was specific to disruption of molecular recognition by human
MHC II, as designed.containing eight mutations, a 50% reduction in predicted
epitope content, and retention of 50%wild-type activity (Table 1).
The structures of the two Lib3 domains were subsequently
modeled and used as templates in another round of deimmu-
nized library design. The resulting library C targeted five sites
in the catalytic domain and three sites in the cell wall binding
domain (Table S1). Functional screening of 10,000 clones
yielded variant Lib4, which deleted 10/16 DR4 epitopes (Fig-
ure 1). Relative to its Lib3 starting template, Lib4 contained
one additional mutation each in the catalytic and cell wall binding
domains, and retained equivalent antibacterial activity (Table 1).
The domains of Lib4 were used in another iterative round of
modeling and deimmunized library design, yielding library D
(Table S1), from which 10,000 clones were screened to isolate
variant Lib5 (Figure 1). This variant deleted 13 of 16 putative
DR4 epitopes, yet retained 50% wild-type expression and 50%
antibacterial activity (Table 1). Compared with variant Opt4, the
best enzyme from the individual protein design efforts, Lib5 ex-
hibited both a lower predicted epitope score and higher
measured functionality (Figure 1).
Further library construction and screening efforts (library E,
Table S1) failed to identify additional functional constructs;
therefore, the 13-mutation Lib5 variant was designated the
lead candidate for further analysis. It is interesting that the three
putative epitopes remaining in variant Lib5 (33-YGVDFFMTI-
41, 38-FMTIGTPVK-46, and 116-FQRMDNTFS-124, Figure 2A)
either encompass or are adjacent to amino acids responsible
for active site Zn2+ coordination (His32, Asp36, and His115).
This fact may explain the elusive nature of functional mutations
within these regions; screening of diverse library popula-
tions (Table S1) identified only one functional substitution in re-
gion 33–46 and two in region 116–124 (Table 1). Together, Lib5
mutations resulted in a 10C reduction in thermostability
relative to LSTWT (Tm = 48.64 ± 0.09
C versus 59.2 ± 0.3C,
respectively).Chemistry & Biology 22,Epitope-Depleted Designs Display Significantly
Reduced Immunogenicity In Vivo
We next sought to assess the extent to which epitope depletion
impacted in vivo immunogenicity. Anti-LST antibody responses
were assessed in both C57Bl/6 and transgenic DR4 mice, the
latter of which are null for endogenous murine MHC II but
bear a chimeric MHC II receptor derived from human HLA
DRB1*0401 (Ito et al., 1996). As a stringent benchmark for dei-
mmunization, mice were immunized subcutaneously with pro-
tein in complete Freund’s adjuvant (CFA), a powerful immunos-
timulant. Two weeks after a single immunization with LSTWT, all
DR4 mice mounted a potent anti-LST IgG antibody response,
with titers between 1:150 and 1:1700 (Figure 3A). In contrast,
mice immunized with Opt4 showed a striking reduction in titers;
only two of five mice exhibited any detectable anti-LST anti-
bodies, and even those were substantially reduced relative to
LSTWT immunized animals (Figure 3A). Variant Lib5 also elicited
a reduced antibody response; only one animal exhibited high
antibody titers (1:1,200), three showed significantly lower anti-
body titers (1:15 to 1:26), and one mouse exhibited near back-
ground levels of anti-LST antibodies (Figure 3B). Importantly,
both LSTWT and Opt4 were equally immunogenic in the C57Bl/
6 laboratory mouse strain (Figure 3C), while Lib5 was actually
more immunogenic than LSTWT (IgG titers 1:4,400 to 1:15,000
versus 1:560 to 1:2,100, respectively) (Figure 3D). Thus, the
striking reductions in Opt4 and Lib5 immunogenicity were spe-
cifically associated with disruption of molecular recognition by
human DR4, as opposed to the native murine MHC II.
It is interesting that although the protein design process was
blinded to all but allele DR4, ProPred predictions indicated that
neither Opt4 nor Lib5 contained neoepitopes for seven other
representative human DRB1 alleles (Figure S1). In fact, over
and above the 11 putative DR4 epitopes deleted fromOpt4, pre-
dictions suggested that 12 epitopes associated with alleles DR1,
DR3, DR7, DR13, and DR15 had also been deleted. Similarly for629–639, May 21, 2015 ª2015 Elsevier Ltd All rights reserved 633
Figure 4. Deimmunized Lysostaphin Manifests Therapeutic Advantages in Humanized DR4 Mice
(A) Immunization, infection, and treatment key. Routes of administration: s.c., subcutaneous; i.v., intravenous; i.p., intraperitoneal. Immunizations were adjuvant
free.
(B) Timeline of the experimental design. Three animals per groupwere preimmunized with three weekly s.c. injections of LSTWT or Lib5 before undergoing a series
of recurrent MRSA infections followed by repeated treatment with LSTWT or Lib5, respectively.
(C) Week 3 immunogenicity of LSTWT (gray) and Lib5 (green) asmeasured by protein-specific IgG ELISA of serum. Byweek 3, LSTWTmice exhibited high antibody
titers, whereas two out of three Lib5 immunized mice exhibited low-level titers.
(D)Week 3 efficacy in a systemic bacteremiamodel. Mice were treated i.v. with LSTWT (gray), Lib5 (green), or PBS (magenta). Both enzymes rescued 100%of their
respective treatment groups, whereas the PBS sham treatment did not.
(E) Week 4 immunogenicity. All mice demonstrated increased anti-LST titers relative to week 3, but the two low-titer Lib5 mice continued to exhibit a weaker
immune response. Mice that were not rescued in subsequent efficacy studies are marked with a red cross.
(F) Week 4 efficacy. LSTWT failed to rescue any mice, and similarly neither the high-titer Lib5 mouse nor the PBS mouse survived. The two lower-titer Lib5 mice
were both rescued by the Lib5 treatment.
(G) Week 5 immunogenicity. The two surviving Lib5 mice again exhibited increased titers, but titers remained below that of the week 4 LSTWT group.
(H) Week 5 efficacy. One of the surviving mice was treated with Lib5 and survived, whereas the second mouse was given a PBS sham treatment and did not.Lib5, in addition to deletion of 13 DR4-restricted epitopes,
ProPred predicted deletion of 18 additional epitopes associated
with the other seven DRB1 alleles (Figure S1).
Lysostaphin Deimmunization Translates into Improved
Therapeutic Efficacy
In many scenarios, therapeutic application of LST might require
repeated administration to fully eradicate S. aureus infections.
Therefore, to more closely mimic potential clinical applications,
we monitored the immunogenicity of LSTWT and Lib5 during
weekly dosing in the absence of adjuvant (Figures 4A and 4B).634 Chemistry & Biology 22, 629–639, May 21, 2015 ª2015 ElsevierSeven days after a third immunization, all DR4 mice receiving
LSTWT had mounted a relatively strong immune response, with
anti-LST titers in the 1:40 to 1:160 range (Figure 4C). During
the same time frame, only one of three mice immunized with
Lib5 developed high antibody titers (1:120) while the other two
Lib5 mice exhibited titers only marginally above background.
Using an S. aureus recurrent bacteremia model, we next eval-
uated the extent to which LST immunogenicity impacted in vivo
efficacy. Following determination of antibody titers at week 3, the
aforementioned DR4 mice were infected by intraperitoneal
administration of 2 3 108 colony-forming units (CFU) ofLtd All rights reserved
methicillin-resistant S. aureus (MRSA) strain USA400. One hour
later, mice were given a 500-mg intravenous bolus of LSTWT or
Lib5, respectively. Both enzymes rescued their respective
groups from this initial infection, whereas a control mouse given
a PBS sham treatment had to be sacrificed because of excessive
morbidity (Figure 4C).
Oneweek later, antibody titershad increased forboth theLSTWT
group (1:300 to 1:650) and the Lib5 group (one mouse >1:1000,
with the remaining two between 1:15 and 1:20), but the latter
continued to exhibit a lower overall trend (Figure 4D). Mice were
now infected with 109 CFU of MRSA and again treated 1 hr later
with a 500-mg intravenous bolus of the respective enzyme. In
this second infection cycle, where mice had developed higher
antibody titers, LSTWT failed to rescue any of the three treated
mice (Figure 4D). Similarly, the single Lib5 mouse exhibiting high
antibody titers succumbed to the infection, but the two lower-titer
Lib5 mice were rescued from the second MRSA challenge.
The following week, antibody titers in the two surviving Lib5
mice were found to have increased yet again (1:70 and 1:120,
Figure 4E), but notably they remained below the week 4 LSTWT
titers. Following a third infection cycle with MRSA, one mouse
was treated with Lib5 and survived, whereas the second mouse
was given a PBS sham and succumbed to the infection (Fig-
ure 4E). As a whole these results show that humanized DR4
mice mounted a strong immune response to LSTWT, even in
the absence of adjuvant. During repeated administration, the
weekly increase in anti-LSTWT antibody titers correlated with
loss of efficacy. Conversely, immune responses were attenuated
in two of three mice receiving the Lib5 deimmunized variant, and
once again in vivo efficacy tracked with anti-LST antibody titers.
Lib5 exerted potent antibacterial efficacy against as many as
three consecutive challenges with MRSA.
Throughout the study, anti-LST antibody titers below 1:256
correlated with enzyme-mediated rescue from S. aureus infec-
tion, whereas titers above 256 were universally associated with
failure of the antibacterial enzyme therapy. The capacity of
variant Lib5 to mitigate anti-drug antibody responses therefore
manifested as enhanced efficacy relative to LSTWT.
DISCUSSION
LST is a promising antibacterial drug candidate with potent
bactericidal activity toward S. aureus in planktonic and biofilm
culture, in metabolically active and inactive states, and toward
both drug-sensitive and drug-resistant strains. However, the
bacterial origins of the enzyme contribute to a variety of immuno-
genicity-related issues in mice, rats, rabbits, dogs, non-human
primates, and human subjects (Kokai-Kun, 2012). As with
many foreign proteins, therefore, immunogenicity represents a
significant barrier to LST clinical translation and widespread
therapeutic application. Efforts to deimmunize LST by chemical
conjugation to polyethylene glycol (PEGylation) initially showed
promising results (Walsh et al., 2003), but follow-up studies sub-
sequently demonstrated that covalent coupling of LST to PEG
led to complete loss of activity (Kokai-Kun, 2012). This latter
observation is consistent with the inactivation of other antibacte-
rial enzymes following PEGylation (Resch et al., 2011).
We hypothesized that LST could instead be deimmunized by
mutagenic deletion of T cell epitopes, and in other studies weChemistry & Biology 22,have shown that deletion of putative epitopes in the LST catalytic
domain resulted in a large reduction of the immunostimulatory
activity of the enzyme toward splenocytes from humanized
mice (Blazanovic et al., 2015). Here, we sought to complement
and extend that work by demonstrating that more extensive pro-
tein-wide epitope depletion could suppress the anti-LST anti-
body response in vivo, thereby enhancing therapeutic efficacy.
As a proof of concept, we first sought to fully deplete all 16 of
the predicted DR4-restricted epitopes of LST. Initial efforts to
simultaneously target all prospective immunogenic subse-
quences failed to produce a folded and functional enzyme.
However, reversion of only four problematic mutations in one
engineered design yielded an expressible ten-mutation variant
predicted to delete 11 of 16 DR4 epitopes. This extensively de-
immunized candidate elicited little to no anti-drug antibody
response in DR4 transgenicmice, whereas thewild-type enzyme
proved to be highly immunogenic. Unfortunately, the low resid-
ual antibacterial activity of the variant precluded in vivo efficacy
testing, and additional molecular engineering was necessary to
assess the extent to which epitope depletion might enhance
therapeutic performance.
Directed evolution is one powerful strategy by which to
achieve molecular gain of function (Brustad and Arnold, 2011;
Goldsmith and Tawfik, 2012), and we considered the possibility
that high-throughput screening of combinatorial LST libraries
might yield deimmunized yet active antibiotics. The single prior
example of library-based protein deimmunization is that of
Escherichia coli asparaginase, an important therapeutic for
childhood acute lymphoblastic leukemia. As a bacterial enzyme,
asparaginase suffers from prevalent anti-drug immune reactions
(45%–75%of human subjects), andwhile a PEGylated version of
the enzyme is approved by the US Food and Drug Administra-
tion, it suffers from a 50% loss of activity and remains immuno-
genic in 5%–18% of patients (Avramis and Panosyan, 2005). In
pursuit of better deimmunized candidates, Cantor et al. (2011)
combined immunoinformatic epitope prediction with combina-
torial library construction and functional screening. Their strat-
egy of ‘‘T cell epitope removal using neutral drift’’ achieved a
marked reduction in asparaginase immunogenicity in transgenic
DR4 mice, but this success was reliant on ultra-high-throughput
screening capabilities. Specifically, their workflow included flow
cytometric screening of approximately 107 clones in each of five
successive libraries, from which a small fraction were found to
be functional and an even smaller fraction were adventitiously
deimmunized. While a similarly powerful flow cytometric screen
for bacteriolytic enzymes could enable the same approach with
LST (Scanlon et al., 2014), we sought here to leverage library
design algorithms that might facilitate biotherapeutic deimmuni-
zation in cases where screening throughput is limited to a few
thousand clones.
Tomake the best use of our screening capabilities, we compu-
tationally optimized focused libraries that were enriched in vari-
ants having good predicted energies yet low epitope content.
Structure-based library design via SOCoM (Verma et al., 2015)
identifies optimal sets of target positions and alternative amino
acids such that resulting mutation combinations exhibit good
structural energies when averaged over an entire library. By aug-
menting SOCoM with an epitope score evaluation and inte-
grating it in a Pareto optimization framework (He et al., 2012),629–639, May 21, 2015 ª2015 Elsevier Ltd All rights reserved 635
we generated libraries deemed beneficial under both criteria.
This computationally guided design strategy enabled construc-
tion of small but diverse libraries compatible with moderate-
throughput screening on agar medium or in microtiter plates.
Four rounds of computationally guided directed evolution pro-
duced a 13-mutation LST variant whose reduced in vivo
immunogenicity translated into enhanced clearance of MRSA
infections in a humanized mouse model. The literature on T cell
epitope deletion offers successful examples in which reduced
immunogenicity and retained in vivo efficacy are assessed inde-
pendently (Cizeau et al., 2009; Mazor et al., 2014), but to the best
of our knowledge the current study is the first direct demonstra-
tion that a T cell epitope-depleted variant manifests therapeutic
advantages relative to the wild-type counterpart.
Immunogenicity is now awidely recognized risk factor for ther-
apeutic proteins, and deimmunization by T cell epitope deletion
is one increasingly attractive option for dealing with this issue.
Empowered by advances in experimental methodologies (Mazor
et al., 2012; Cantor et al., 2011; Harding et al., 2010), epitope pre-
diction tools (Wang et al., 2010; Bryson et al., 2010; Jawa et al.,
2013), and protein design algorithms (Parker et al., 2013; Choi
et al., 2013; King et al., 2014), T cell epitope deletion is being
applied to a progressively larger number of therapeutic candi-
dates. Early clinical data from epitope-depleted biotherapeutics
suggest that molecular engineering has had the desired effect
in human patients (Morris et al., 2005; Entwistle et al.,
2012), although to date no comparative clinical data for T cell
epitope-depleted and wild-type versions of the same bio-
therapeutic have been reported. Deimmunized variants of
Pseudomonas exotoxin should soon be entering clinical trials
(Mazor et al., 2014), and comparison with results from the wild-
type immunotoxin SS1P (Kreitman et al., 2009) will provide
new insights into the clinical utility of T cell epitope deletion. In
the interim, the work described here provides key evidence sup-
porting the practical utility of this protein deimmunization strat-
egy. Using a relevant humanized mouse model, we have drawn
direct connections between depletion of putative T cell epitopes,
mitigation of in vivo anti-drug antibody responses, and enhance-
ment of therapeutic efficacy. These results, and the broad appli-
cability of the enabling computational tools, bode well for the
future development of clinically useful antibacterial lysins, and
more generally for the prospect of engineering deimmunized bio-
therapeutics from a variety of non-human sources.
SIGNIFICANCE
Staphylococcus aureus is a particularly deadly pathogen
responsible for nearly half of all deaths associated with
drug-resistant bacteria in the United States. Lysostaphin is
a potent anti-staphylococcal enzyme with bona fide thera-
peutic potential, but unfortunately this promising antibacte-
rial agent has proved to be excessively immunogenic in
higher animals. Here, we use advanced protein design tools
to engineer lysostaphin variants in which immunogenic
T cell epitopes have been deleted. We show that deimmu-
nized lysostaphin is able to clear recurrent, drug-resistant,
S. aureus bacteremia in mice having humanized immune
systems, whereas wild-type lysostaphin fails to rescue
mice from repeated infections, which are coincident with636 Chemistry & Biology 22, 629–639, May 21, 2015 ª2015 Elsevierescalating anti-drug antibody titers. While the tripartite link-
age between T cell epitope deletion, reduction in anti-drug
antibody response, and resulting enhancement of therapeu-
tic efficacy has been a long-standing assumptionmotivating
research in this area, the controlled head-to-head studies
described here represent a milestone in biotherapeutic
design and deimmunization. Namely, the results provide
the first direct demonstration that depletion of putative
T cell epitopes in biologics manifests enhanced therapeutic
efficacy.
EXPERIMENTAL PROCEDURES
Materials
Primers were ordered with standard desalting from IDT Technologies. Restric-
tion enzymes and Phusion DNA polymerase for molecular cloning were
purchased from New England Biolabs. All other reagents and supplies were
from VWR Scientific unless specifically noted.
P. pastoris expression vector pPIC9 and P. pastoris strain GS115(his4) were
purchased from Invitrogen. E. coli DH5a [F F80lacZDM15 D(lacZYA-argF)
U169 recA1 endA1 hsdR17 (rK, mK+) phoA supE44 l thi-1 gyrA96 relA1],
S. aureus strain SA113, and MRSA strain USA400 were obtained from the
American Type Culture Collection.
The accession numbers for lysostaphin sequences Opt4 and Lib5 reported
in this paper are Genbank: KR381776 and KR381777, respectively.
LST Homology Models
Homology models for the two domains were constructed as follows. Three
template structures from LytM were selected for the catalytic domain
(2B0P:A, 2B44:A, and 1QWY:A) (Firczuk et al., 2005; Odintsov et al., 2004) (Fig-
ure S2). The cell wall binding domain was constructed using a single template
structure (1R77:A, cell wall targeting domain structure of ALE-1, a lysostaphin
homolog) (Lu et al., 2006). The domain models were constructed separately
using MODELLER (Eswar et al., 2008), and a templateless region in the cata-
lytic domain (24-PLGINGG-30) was modeled using FREAD (Choi and Deane,
2010). The bestmodels were selected in terms of the DOPE statistical potential
function score (Shen and Sali, 2006).
Preprocessing of Mutation Choices
For each domain, three iterations of PSI-BLAST (Altschul et al., 1997) were run
against the non-redundant database to find homologs. Multiple sequence
alignments (MSA) were constructed and curated to yield sets of 114 represen-
tative catalytic domain homologs and 23 representative cell wall binding
domain sequences. Amino acids were identified at each position in each
MSA and subsequently used as possible mutations for design.
The mutational choices were expanded for library design, since screening
allows for riskier substitutions. In particular, Chou-Fasman (Chou and Fasman,
1974) propensities were used to identify residues likely to be acceptable in the
wild-type secondary structure environment, according to a stringent threshold
of 1.5. In addition, since the library was constructed with degenerate oligonu-
cleotides that can incorporate additional amino acids beyond the desired
ones (inclusive of wild-type residue), these additions were allowed, as long
as the desired to undesired ratio within a degenerate oligonucleotide remained
above 2:3.
Structure-Based Design of Individual Variants
To generate epitope-depleted designs, the structure-based deimmunization
methodEpiSweepwasapplied to eachdomain aspreviously described (Parker
et al., 2013). OSPREY (ver. 2.0) (Chen et al., 2009; Gainza et al., 2013) was used
to assess one- and two-body energy terms for possible rotamers (Lovell et al.,
2000) for themutational choices, according to theAMBER force field (Pearlman
et al., 1995) and a reference energy (Lippow and Tidor, 2007). ProPred (Singh
and Raghava, 2001) at a 5% threshold was used to assess DR4 epitope con-
tent, characterizing each 9mer as either a binder or a non-binder. A set of 20 en-
ergy optimal and near-optimal fully depleted designs were identified for each
domain via the EpiSweep optimization algorithm. The most energy optimalLtd All rights reserved
catalytic domain design contained a mutation at S124, which was previously
found to be less desirable than the alternative double mutation N121G and
S122G, which removes the same epitope (Blazanovic et al., 2015). Thus,
Opt1 was selected so as to possess the most energy optimal design for the
cell wall binding domain and the alternative double mutation in the C-terminal
portion of the catalytic domain (N121G and S122G) (Table 1).
Structure-Based Design of Deimmunized Libraries
To design combinatorial libraries enriched in stable, deimmunized variants, we
developed a method called EpiSOCoM, which augments the SOCoM struc-
ture-based library design approach (Verma et al., 2015) with epitope analysis,
and uses a sweep-based Pareto optimization algorithm (Parker et al., 2013) to
simultaneously optimize both energy and epitope content. Given a set of
possible positions at which to mutate and possible amino acids to incorporate
at those positions (as described above in Preprocessing), along with a desired
library size, EpiSOCoM selects a subset of the positions and subsets of the
substitutions at those positions. It thereby specifies the construction of a
library comprising all combinations of the substitutions and corresponding
wild-type residues. EpiSOCoM optimizes a library for the average energy
score and the average epitope score over its constituent variants, so that in
general variants will be ‘‘good.’’ Its Pareto optimization algorithm identifies
all library designs (positions and substitutions) making undominated trade-
offs between the two scores, in that no other library design is better for
both. A detailed description of the EpiSOCoM implementation is described
in the Supplemental Experimental Methods.
Protein Expression, Purification, and Characterization
LST and its derivatives were secreted from P. pastoris and purified as previ-
ously described (Zhao et al., 2014). Endotoxin was removed from the protein
preparation by Triton X-114 extraction (Liu et al., 1997), and endotoxin levels
in all samples were less than 0.1 EU/mg of protein. Protein expression levels
were estimated by densitometry analysis of SDS-PAGE gels. The activities
of proteins were assessed by determination of minimal inhibitory concentra-
tion (MIC) against S. aureus strain SA113, and are reported as a normalized
percentage relative to theMIC dilution determined for LSTWT (i.e., 50% activity
is two-fold higher MIC relative to wild-type, and 25% activity is four-fold higher
MIC relative to wild-type).
Library Construction and Screening
LST libraries were constructed by splice-overlapping PCR with the primers
shown in Table S2. The PCR products were ligated into pPIC9 vector and
transformed into DH5a. Constructs were sequence verified and transformed
into P. pastoris by electroporation. Active library members were identified
using a moderate-throughput plate halo formation assay, as described
previously (Zhao et al., 2014). Approximately 10,000 clones were screened
for each round. The genes encoding the ten variants exhibiting the largest
halos were PCR amplified, subcloned back into pPIC9, sequenced, and re-
transformed into freshly prepared P. pastoris cells for functional validation
by determination of MIC. The most deimmunized and functional variant was
used as the starting point for the subsequent round of library construction
and screening.
In Vivo Studies
The protocols for animal infection, treatment, and immunization were
approved by the Institutional Animal Care and Use Committee of Dartmouth
College, in accordance with the Association for the Assessment and Accred-
itation of Laboratory Animal Care Guidelines. All efforts weremade tominimize
animal suffering.
In Vivo Immunogenicity
A 100-ml volume of 100 mg purified wild-type or variant enzyme in CFA was in-
jected subcutaneously in either DR4 (n = 5 per group) or C57Bl/6 (n = 4 per
group) mice. Thirteen days following immunization, serum was collected and
anti-LST IgG antibody titers (specific to wild-type or variant protein) were
measured by ELISA. Reported titers were defined as the serum fold dilution
yielding an absorbance of 1.5.Chemistry & Biology 22,In Vivo Efficacy
Prior to bacterial challenge, the immune systems of DR4mice (n = 3 per group)
were primed three times with weekly subcutaneous injections of 100 mg of
LSTWT or Lib5 variant in sterile PBS (PBS: 2.7 mM KCl, 1.5 mM KH2PO4,
8.9 mM Na2HPO4, 136.9 mM NaCl [pH 7.4]) with no adjuvant. Anti-LST anti-
body titers were determined as described above. For the first cycle of infection
and treatment, mice were challenged with intraperitoneal administration of 23
108 CFU S. aureus strain USA400 in a 3% suspension of porcine mucin, and
1 hr later were treated by intravenous tail vein administration of 500 mg of
LSTWT or Lib5 variant in sterile PBS. Mice that were rescued by the enzyme
treatment underwent similar infection and treatment cycles at weekly intervals,
where follow-up bacterial challenges contained 1 3 109 CFU USA400.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2015.04.017.
ACKNOWLEDGMENTS
This work was supported by the National Institute of Allergy and Infectious Dis-
eases 1R21AI098122 and the National Institute of General Medical Sciences
R01-GM-098977. H.Z. was supported in part by funds from the Dartmouth
Cystic Fibrosis Research Development Program. We also gratefully acknowl-
edge computational resources provided by NSF grant CNS-1205521 and the
technical support of the Dartmouth Transgenic and Genetic Construct Shared
Resource (P30 CA023108) and Immunology COBRE Core C (P20 RR15639).
Karl E. Griswold and Chris Bailey-Kellogg are Dartmouth faculty and co-
members of Stealth Biologics, LLC, a Delaware biotechnology company.
These authors acknowledge that there is a potential financial conflict of inter-
est related to their associations with this company, and they hereby affirm that
the data presented in this paper is free of any bias. This work has been
reviewed and approved as specified in Karl E. Griswold’s and Chris Bailey-
Kellogg’s Dartmouth conflict of interest management plans. The remaining
authors declare no conflict of interest.
Received: February 25, 2015
Revised: April 16, 2015
Accepted: April 17, 2015
Published: May 21, 2015
REFERENCES
Aggarwal, R.S. (2014). What’s fueling the biotech engine—2012 to 2013. Nat.
Biotechnol. 32, 32–39.
Altschul, S.F., Madden, T.L., Scha¨ffer, A.A., Zhang, J., Zhang, Z., Miller, W.,
and Lipman, D.J. (1997). Gapped BLAST and PSI-BLAST: a new generation
of protein database search programs. Nucleic Acids Res. 25, 3389–3402.
Avramis, V.I., and Panosyan, E.H. (2005). Pharmacokinetic/pharmacodynamic
relationships of asparaginase formulations: the past, the present and recom-
mendations for the future. Clin. Pharmacokinet. 44, 367–393.
Blazanovic, K., Zhao, H., Choi, Y., Li, W., Salvat, R.S., Osipovitch, D.C., Fields,
J., Moise, L., Berwin, B.L., Fiering, S.N., et al. (2015). Structure-based redesign
of lysostaphin yields potent anti-staphylococcal enzymes that evade immune
cell surveillance. Mol. Ther. Methods Clin. Dev. http://dx.doi.org/10.1038/
mtm.2015.21.
Brustad, E.M., and Arnold, F.H. (2011). Optimizing non-natural protein function
with directed evolution. Curr. Opin. Chem. Biol. 15, 201–210.
Bryson, C.J., Jones, T.D., and Baker, M.P. (2010). Prediction of immunoge-
nicity of therapeutic proteins: validity of computational tools. BioDrugs 24, 1–8.
Cantor, J.R., Yoo, T.H., Dixit, A., Iverson, B.L., Forsthuber, T.G., and Georgiou,
G. (2011). Therapeutic enzyme deimmunization by combinatorial T-cell
epitope removal using neutral drift. Proc. Natl. Acad. Sci. USA 108, 1272–
1277.629–639, May 21, 2015 ª2015 Elsevier Ltd All rights reserved 637
Chen, C.Y., Georgiev, I., Anderson, A.C., and Donald, B.R. (2009).
Computational structure-based redesign of enzyme activity. Proc. Natl.
Acad. Sci. USA 106, 3764–3769.
Choi, Y., and Deane, C.M. (2010). FREAD revisited: accurate loop structure
prediction using a database search algorithm. Proteins 78, 1431–1440.
Choi, Y., Griswold, K.E., and Bailey-Kellogg, C. (2013). Structure-based rede-
sign of proteins for minimal T-cell epitope content. J. Comput. Chem. 34,
879–891.
Chou, P.Y., and Fasman, G.D. (1974). Prediction of protein conformation.
Biochemistry 13, 222–245.
Cizeau, J., Grenkow, D.M., Brown, J.G., Entwistle, J., and MacDonald, G.C.
(2009). Engineering and biological characterization of VB6-845, an anti-
EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant
toxin bouganin. J. Immunother. 32, 574–584.
Entwistle, J., Brown, J.G., Chooniedass, S., Cizeau, J., and MacDonald, G.C.
(2012). Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with
reduced immunogenic potential. Cancer Biother. Radiopharm. 27, 582–592.
Eswar, N., Eramian, D., Webb, B., Shen, M.Y., and Sali, A. (2008). Protein
structure modeling with MODELLER. Methods Mol. Biol. 426, 145–159.
Firczuk, M., Mucha, A., and Bochtler, M. (2005). Crystal structures of active
LytM. J. Mol. Biol. 354, 578–590.
Gainza, P., Roberts, K.E., Georgiev, I., Lilien, R.H., Keedy, D.A., Chen, C.Y.,
Reza, F., Anderson, A.C., Richardson, D.C., Richardson, J.S., and Donald,
B.R. (2013). OSPREY: protein design with ensembles, flexibility, and provable
algorithms. Methods Enzymol. 523, 87–107.
Goldsmith, M., and Tawfik, D.S. (2012). Directed enzyme evolution: beyond
the low-hanging fruit. Curr. Opin. Struct. Biol. 22, 406–412.
Grigoryan, G., Zhou, F., Lustig, S.R., Ceder, G., Morgan, D., and Keating, A.E.
(2006). Ultra-fast evaluation of protein energies directly from sequence. PLoS
Comput. Biol. 2, e63.
Grigoryan, G., Reinke, A.W., and Keating, A.E. (2009). Design of protein-inter-
action specificity gives selective bZIP-binding peptides. Nature 458, 859–864.
Harding, F.A., Liu, A.D., Stickler, M., Razo, O.J., Chin, R., Faravashi, N., Viola,
W., Graycar, T., Yeung, V.P., Aehle, W., et al. (2005). A beta-lactamase with
reduced immunogenicity for the targeted delivery of chemotherapeutics using
antibody-directed enzyme prodrug therapy. Mol. Cancer Ther. 4, 1791–1800.
Harding, F.A., Stickler, M.M., Razo, J., and DuBridge, R.B. (2010). The immu-
nogenicity of humanized and fully human antibodies: residual immunogenicity
resides in the CDR regions. MAbs 2, 256–265.
He, L., Friedman, A.M., and Bailey-Kellogg, C. (2012). A divide-and-conquer
approach to determine the Pareto frontier for optimization of protein engineer-
ing experiments. Proteins 80, 790–806.
Ito, K., Bian, H.J., Molina, M., Han, J., Magram, J., Saar, E., Belunis, C., Bolin,
D.R., Arceo, R., Campbell, R., et al. (1996). HLA-DR4-IE chimeric class II trans-
genic, murine class II-deficient mice are susceptible to experimental allergic
encephalomyelitis. J. Exp. Med. 183, 2635–2644.
Jawa, V., Cousens, L.P., Awwad, M., Wakshull, E., Kropshofer, H., and De
Groot, A.S. (2013). T-cell dependent immunogenicity of protein therapeutics:
preclinical assessment and mitigation. Clin. Immunol. 149, 534–555.
King, C., Garza, E.N., Mazor, R., Linehan, J.L., Pastan, I., Pepper, M., and
Baker, D. (2014). Removing T-cell epitopes with computational protein design.
Proc. Natl. Acad. Sci. USA 111, 8577–8582.
Kokai-Kun, J.F. (2012). Lysostaphin: a silver bullet for Staph. In Antimicrobial
Drug Discovery, Vol. 22, G. Tegos and E. Mylonakis, eds (CABI), pp. 147–165.
Kreitman, R.J., Hassan, R., Fitzgerald, D.J., and Pastan, I. (2009). Phase I trial
of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin.
Cancer Res. 15, 5274–5279.
Lippow, S.M., and Tidor, B. (2007). Progress in computational protein design.
Curr. Opin. Biotechnol. 18, 305–311.
Liu, S., Tobias, R., McClure, S., Styba, G., Shi, Q., and Jackowski, G. (1997).
Removal of endotoxin from recombinant protein preparations. Clin.
Biochem. 30, 455–463.638 Chemistry & Biology 22, 629–639, May 21, 2015 ª2015 ElsevierLovell, S.C., Word, J.M., Richardson, J.S., and Richardson, D.C. (2000). The
penultimate rotamer library. Proteins 40, 389–408.
Lu, J.Z., Fujiwara, T., Komatsuzawa, H., Sugai, M., and Sakon, J. (2006). Cell
wall-targeting domain of glycylglycine endopeptidase distinguishes among
peptidoglycan cross-bridges. J. Biol. Chem. 281, 549–558.
Mazor, R., Vassall, A.N., Eberle, J.A., Beers, R., Weldon, J.E., Venzon, D.J.,
Tsang, K.Y., Benhar, I., and Pastan, I. (2012). Identification and elimination
of an immunodominant T-cell epitope in recombinant immunotoxins based
on Pseudomonas exotoxin A. Proc. Natl. Acad. Sci. USA 109, E3597–
E3603.
Mazor, R., Eberle, J.A., Hu, X., Vassall, A.N., Onda, M., Beers, R., Lee, E.C.,
Kreitman, R.J., Lee, B., Baker, D., et al. (2014). Recombinant immunotoxin
for cancer treatment with low immunogenicity by identification and silencing
of human T-cell epitopes. Proc. Natl. Acad. Sci. USA 111, 8571–8576.
Morris, M.J., Divgi, C.R., Pandit-Taskar, N., Batraki, M., Warren, N., Nacca, A.,
Smith-Jones, P., Schwartz, L., Kelly, W.K., Slovin, S., et al. (2005). Pilot trial of
unlabeled and indium-111-labeled anti-prostate-specific membrane antigen
antibody J591 for castrate metastatic prostate cancer. Clin. Cancer Res. 11,
7454–7461.
Odintsov, S.G., Sabala, I., Marcyjaniak, M., and Bochtler, M. (2004). Latent
LytM at 1.3A resolution. J. Mol. Biol. 335, 775–785.
Osipovitch, D.C., Parker, A.S., Makokha, C.D., Desrosiers, J., Kett, W.C.,
Moise, L., Bailey-Kellogg, C., and Griswold, K.E. (2012). Design and analysis
of immune-evading enzymes for ADEPT therapy. Protein Eng. Des. Sel 25,
613–623.
Parker, A.S., Zheng, W., Griswold, K.E., and Bailey-Kellogg, C. (2010).
Optimization algorithms for functional deimmunization of therapeutic proteins.
BMC Bioinformatics 11, 180.
Parker, A.S., Griswold, K.E., and Bailey-Kellogg, C. (2011). Optimization of
therapeutic proteins to delete T-cell epitopes while maintaining beneficial res-
idue interactions. J. Bioinform. Comput. Biol. 9, 207–229.
Parker, A.S., Choi, Y., Griswold, K.E., and Bailey-Kellogg, C. (2013).
Structure-guided deimmunization of therapeutic proteins. J. Comput. Biol.
20, 152–165.
Pearlman, D.A., Case, D.A., Caldwell, J.W., Ross, W.S., Cheatham, T.E., III,
DeBolt, S., Ferguson, D., Seibel, G., and Kollman, P. (1995). Amber, a package
of computer-programs for applying molecular mechanics, normal-mode anal-
ysis, molecular-dynamics and free-energy calculations to simulate the struc-
tural and energetic properties of molecules. Comput. Phys. Commun. 91,
1–41.
Resch, G., Moreillon, P., and Fischetti, V.A. (2011). PEGylating a bacterio-
phage endolysin inhibits its bactericidal activity. AMB Express 1, 29.
Rohl, C.A., Strauss, C.E., Misura, K.M., and Baker, D. (2004). Protein structure
prediction using Rosetta. Methods Enzymol. 383, 66–93.
Sabala, I., Jagielska, E., Bardelang, P.T., Czapinska, H., Dahms, S.O., Sharpe,
J.A., James, R., Than, M.E., Thomas, N.R., and Bochtler, M. (2014). Crystal
structure of the antimicrobial peptidase lysostaphin from Staphylococcus
simulans. FEBS J. 281, 4112–4122.
Salvat, R., Moise, L., Bailey-Kellogg, C., and Griswold, K.E. (2014). A high
throughput MHC II binding assay for quantitative analysis of peptide epitopes.
J. Vis. Exp. 85, http://dx.doi.org/10.3791/51308.
Salvat, R., Bailey-Kellogg, C., and Griswold, K.E. (2015). Protein deimmuniza-
tion via structure-based design enables efficient epitope deletion at highmuta-
tional loads. Biotechnol. Bioeng. http://dx.doi.org/10.1002/bit.25554.
Scanlon, T.C., Dostal, S.M., and Griswold, K.E. (2014). A high-throughput
screen for antibiotic drug discovery. Biotechnol. Bioeng. 111, 232–243.
Schellekens, H. (2002). Immunogenicity of therapeutic proteins: clinical impli-
cations and future prospects. Clin. Ther. 24, 1720–1740.
Shen,M.Y., and Sali, A. (2006). Statistical potential for assessment and predic-
tion of protein structures. Protein Sci. 15, 2507–2524.
Singh, H., and Raghava, G.P. (2001). ProPred: prediction of HLA-DR binding
sites. Bioinformatics 17, 1236–1237.Ltd All rights reserved
Stark, F.R., Thornsva, C., Flannery, E.P., and Artenste, M.S. (1974). Systemic
lysostaphin in man—apparent antimicrobial activity in a neutropenic patient.
New Engl. J. Med. 291, 239–241.
Szweda, P., Schielmann, M., Kotlowski, R., Gorczyca, G., Zalewska, M., and
Milewski, S. (2012). Peptidoglycan hydrolases-potential weapons against
Staphylococcus aureus. Appl. Microbiol. Biotechnol. 96, 1157–1174.
Trombetta, E.S., and Mellman, I. (2005). Cell biology of antigen processing
in vitro and in vivo. Annu. Rev. Immunol. 23, 975–1028.
Verma, D., Grigoryan, G., and Bailey-Kellogg, C. (2015). Structure-based
design of combinatorial mutagenesis libraries. Protein Sci. 24, 895–908.
Walsh, S., Shah, A., and Mond, J. (2003). Improved pharmacokinetics and
reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol.
Antimicrob. Agents Chemother. 47, 554–558.Chemistry & Biology 22,Wang, P., Sidney, J., Kim, Y., Sette, A., Lund, O., Nielsen, M., and Peters, B.
(2010). Peptide binding predictions for HLA DR, DP and DQ molecules. BMC
Bioinformatics 11, 568.
Warmerdam, P.A., Plaisance, S., Vanderlick, K., Vandervoort, P., Brepoels, K.,
Collen, D., and De Maeyer, M. (2002). Elimination of a human T-cell region in
staphylokinase by T-cell screening and computer modeling. Thromb.
Haemost. 87, 666–673.
Zhang, Y., and Skolnick, J. (2004). Scoring function for automated assessment
of protein structure template quality. Proteins 57, 702–710.
Zhao, H., Blazanovic, K., Choi, Y., Bailey-Kellogg, C., and Griswold, K.E.
(2014). Gene and protein sequence optimization for high-level production of
fully active and aglycosylated lysostaphin in Pichia pastoris. Appl. Environ.
Microbiol. 80, 2746–2753.629–639, May 21, 2015 ª2015 Elsevier Ltd All rights reserved 639
